4 629

Cited 12 times in

Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity

DC Field Value Language
dc.contributor.author노재경-
dc.contributor.author라선영-
dc.contributor.author신규호-
dc.contributor.author신상준-
dc.contributor.author이영주-
dc.contributor.author정민규-
dc.contributor.author정재헌-
dc.contributor.author홍수정-
dc.date.accessioned2014-12-20T17:16:41Z-
dc.date.available2014-12-20T17:16:41Z-
dc.date.issued2011-
dc.identifier.issn0030-2414-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/94294-
dc.description.abstractOBJECTIVE: This study compared outcomes between doublet (AP) and triplet (IAP) neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremity. METHODS: A total of 124 patients were enrolled. In the AP group, a doublet regimen of intraarterial cisplatin and intravenous doxorubicin was given to 77 patients from 1991 to 1999. In the IAP group, a triplet regimen of additional intravenous ifosfamide was given to 47 patients from 2000 to 2007. After completion of 3 cycles of chemotherapy, patients underwent surgery. We assessed tumor response according to pathologic tumor necrosis, and treated patients with further adjuvant chemotherapy. RESULTS: The overall pathologic response was excellent with more than 90% tumor necrosis in 74.8% of patients. Total necrosis of tumors was also found in 46 (37.4%) patients. There was no difference between the 2 groups in pathologic response (75.3 vs. 72.3%; p = 0.52) or other clinicopathologic parameters. There was no difference between the 2 groups in recurrence rate (31.2 vs. 31.9%; p = 0.17) or lung metastasis (28.6 vs. 23.4%; p = 0.53). Moreover, there were no statistical differences in median disease-free survival and overall survival between the groups. There was more hematologic toxicity in the IAP group (neutropenia, p = 0.002; thrombocytopenia, p = 0.001; febrile neutropenia, p < 0.001). CONCLUSIONS: The addition of ifosfamide to doxorubicin and cisplatin in neoadjuvant chemotherapy did not show improved outcomes in this study. Further trials are required to elucidate optimal neoadjuvant chemotherapy and effective salvage regimens-
dc.description.statementOfResponsibilityopen-
dc.format.extent107~117-
dc.relation.isPartOfONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdolescent-
dc.subject.MESHAdult-
dc.subject.MESHAntineoplastic CombinedChemotherapyProtocols/therapeutic use*-
dc.subject.MESHBone Neoplasms/drug therapy*-
dc.subject.MESHBone Neoplasms/pathology-
dc.subject.MESHBone Neoplasms/surgery-
dc.subject.MESHChild-
dc.subject.MESHChild, Preschool-
dc.subject.MESHCisplatin/administration & dosage-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHDoxorubicin/administration & dosage-
dc.subject.MESHExtremities/pathology*-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHIfosfamide/administration & dosage-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHLung Neoplasms/secondary-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoadjuvantTherapy-
dc.subject.MESHNeoplasm Recurrence, Local-
dc.subject.MESHNeutropenia/chemically induced-
dc.subject.MESHOsteosarcoma/drug therapy*-
dc.subject.MESHOsteosarcoma/pathology-
dc.subject.MESHOsteosarcoma/surgery-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSurvival Rate-
dc.subject.MESHThrombocytopenia/chemically induced-
dc.subject.MESHTreatmentOutcome-
dc.subject.MESHYoung Adult-
dc.titleComparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorHong S.-
dc.contributor.googleauthorShin S.J.-
dc.contributor.googleauthorJung M.-
dc.contributor.googleauthorJeong J.-
dc.contributor.googleauthorLee Y.J.-
dc.contributor.googleauthorShin K.-H.-
dc.contributor.googleauthorRoh J.K.-
dc.contributor.googleauthorRha S.Y.-
dc.identifier.doi10.1159/000327216-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01290-
dc.contributor.localIdA02086-
dc.contributor.localIdA02105-
dc.contributor.localIdA02960-
dc.contributor.localIdA03606-
dc.contributor.localIdA03714-
dc.contributor.localIdA04410-
dc.contributor.localIdA01316-
dc.relation.journalcodeJ02416-
dc.identifier.eissn1423-0232-
dc.identifier.pmid21677455-
dc.identifier.urlhttp://www.karger.com/Article/FullText/327216-
dc.subject.keywordOsteosarcoma-
dc.subject.keywordNeoadjuvant-
dc.subject.keywordToxicity-
dc.contributor.alternativeNameRoh, Jae Kyung-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.alternativeNameShin, Kyoo Ho-
dc.contributor.alternativeNameShin, Sang Joon-
dc.contributor.alternativeNameLee, Young Joo-
dc.contributor.alternativeNameJung, Min Kyu-
dc.contributor.alternativeNameJung, Jae Hun-
dc.contributor.alternativeNameHong, Soo Jung-
dc.contributor.affiliatedAuthorRoh, Jae Kyung-
dc.contributor.affiliatedAuthorShin, Kyoo Ho-
dc.contributor.affiliatedAuthorShin, Sang Joon-
dc.contributor.affiliatedAuthorLee, Young Joo-
dc.contributor.affiliatedAuthorJung, Min Kyu-
dc.contributor.affiliatedAuthorJung, Jae Hun-
dc.contributor.affiliatedAuthorHong, Soo Jung-
dc.contributor.affiliatedAuthorRha, Sun Young-
dc.rights.accessRightsnot free-
dc.citation.volume80-
dc.citation.number1-2-
dc.citation.startPage107-
dc.citation.endPage117-
dc.identifier.bibliographicCitationONCOLOGY, Vol.80(1-2) : 107-117, 2011-
dc.identifier.rimsid27522-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Orthopedic Surgery (정형외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.